Company Immuneering Corporation

Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the MAPK pathway. The Company’s second product candidate, IMM-6-415, aims to achieve universal-MAPK activity with an accelerated twice-daily oral dosing cadence, also through deep cyclic inhibition of the MAPK pathway. IMM-6-415 is in Investigational New Drug application (IND), enabling studies. Its pipeline also includes Trifecta MEK, RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.

Number of employees: 68